Sex-Related Outcomes of Transcatheter Aortic Valve Implantation With Self-Expanding or BalloonExpandable Valves: Insights from the OPERA-TAVI Registry

Evidence regarding gender -related differences in response to transcatheter aortic valve implantation according to the valve type is lacking. This study aimed to evaluate the impact of gender on the treatment effect of Evolut PRO/PRO+ (PRO) or SAPIEN 3 Ultra (ULTRA) devices on clinical outcomes. The Comparative Analysis of Evolut PRO vs SAPIEN 3 Ultra Valves for Transfemoral Transcatheter Aortic Valve Implantation (OPERA-TAVI) is a multicenter, multinational registry including patients who underwent the latest -iteration PRO or ULTRA implantation. Overall, 1,174 of 1,897 patients were matched based on valve type and compared according to gender, whereas 470 men and 630 women were matched and compared according to valve type. The 30 -day and 1 -year outcomes were evaluated. In the PRO and ULTRA groups, men had a higher co -morbidity burden, whereas women had smaller aortic root. The 30 -day (device success [DS], early safety outcome, permanent pacemaker implantation, patient -prosthesis mismatch, paravalvular regurgitation, bleedings, vascular complications, and all -cause death) and 1 -year outcomes (all -cause death, stroke, and heart failure hospitalization) did not differ according to gender in both valve groups. However, the male gender decreased the likelihood of 30 -day DS with ULTRA versus PRO (p for interaction = 0.047). A higher risk of 30 -day permanent pacemaker implantation and 1 -year stroke and a lower risk of patient -prosthesis mismatch was observed in PRO versus ULTRA, regardless of gender. In conclusion, gender did not modify the treatment effect of PRO versus ULTRA on clinical outcomes, except for 30 -day DS, which was decreased in men (vs women) who received ULTRA (vs PRO). (c) 2024 Elsevier Inc. All rights reserved. (Am J Cardiol 2024;219:60 - 70)